BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.

Kevin Yau Paul Tam Christopher T ChanQueenie HuFreda QiKento T AbeAlexandra Kurtesi Yidi Jiang Jose Estrada-CodecidoTyler BrownLisa LiuAswani SiwakotiJerome A LeisAdeera LevinMatthew J Oliver Karen Colwill Anne-Claude Gingras Michelle A Hladunewich

Published in: Clinical journal of the American Society of Nephrology : CJASN (2023)

In patients with CKD third dose COVID-19 mRNA vaccination with mRNA-1273 elicited higher SARS-CoV-2 anti-RBD levels in comparison to BNT162b2 over a 6-month period.

Keyphrases

sars cov
end stage renal disease
chronic kidney disease
coronavirus disease
respiratory syndrome coronavirus
peritoneal dialysis
newly diagnosed
binding protein
ejection fraction
prognostic factors
patient reported outcomes
patient reported